Literature DB >> 9723438

The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation.

T Böhler1, J Waiser, K Budde, S Lichter, A Jauho, L Fritsche, A Korn, H H Neumayer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9723438     DOI： 10.1016/s0041-1345(98)00588-0

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  10 in total

Review 1.  Everolimus: a review of its use in renal and cardiac transplantation.

Authors:  Christopher Dunn; Katherine F Croom
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.

Authors:  M Majewski; M Korecka; P Kossev; S Li; J Goldman; J Moore; L E Silberstein; P C Nowell; W Schuler; L M Shaw; M A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

3.  Interactions of everolimus and sorafenib in whole blood lymphocyte proliferation.

Authors:  Dipti K Pawaskar; Robert M Straubinger; Gerald J Fetterly; Wen W Ma; William J Jusko
Journal:  Pharm Res       Date:  2012-11-14       Impact factor: 4.200

4.  Rapamycin inhibits GM-CSF-induced neutrophil migration.

Authors:  Julian Gomez-Cambronero
Journal:  FEBS Lett       Date:  2003-08-28       Impact factor: 4.124

5.  Everolimus.

Authors:  Therese M Chapman; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates.

Authors:  N Serkova; L Litt; D Leibfritz; B Hausen; R E Morris; T L James; L Z Benet; U Christians
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

7.  Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats.

Authors:  Michael Deters; Gabriele Kirchner; Therese Koal; Klaus Resch; Volkhard Kaever
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

Review 8.  Clinical pharmacokinetics of everolimus.

Authors:  Gabriele I Kirchner; Ivo Meier-Wiedenbach; Michael P Manns
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.

Authors:  Matthias Helmschrott; Rasmus Rivinius; Thomas Bruckner; Hugo A Katus; Andreas O Doesch
Journal:  Drug Des Devel Ther       Date:  2017-06-07       Impact factor: 4.162

10.  Everolimus induced pneumonitis in a lung transplant recipient.

Authors:  Ambalavanan Arunachalam; Syed Rizwan Ali; Brett J Wakefield; Charles R Lane; Atul C Mehta
Journal:  Oxf Med Case Reports       Date:  2018-04-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.